{
    "organizations": [],
    "uuid": "64867aeb03fa43c5fbd8bc0346429eb5e4c6ae85",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-horizon-discovery-enters-into-an-a/brief-horizon-discovery-enters-into-an-agreement-with-a-immuno-oncology-therapeutics-developer-idUSFWN1Q20SL",
    "ord_in_thread": 0,
    "title": "BRIEF-Horizon Discovery Enters into An Agreement With A Immuno-Oncology Therapeutics Developer​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Horizon Discovery Group Plc:\n* HORIZON DISCOVERY GROUP PLC - ‍ENTERED INTO A NON-EXCLUSIVE OUT-LICENSING AGREEMENT WITH A US-BASED IMMUNO-ONCOLOGY THERAPEUTICS DEVELOPER​\n* HORIZON DISCOVERY -DEAL FOR CO‘S PROPRIETARY TECHNOLOGIES TO SUPPORT DEVELOPMENT,MANUFACTURE OF NOVEL BIOMANUFACTURING CELL LINE FOR COMMERCIAL USE​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-12T20:18:00.000+02:00",
    "crawled": "2018-02-13T15:33:59.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "horizon",
        "discovery",
        "group",
        "plc",
        "horizon",
        "discovery",
        "group",
        "plc",
        "agreement",
        "therapeutic",
        "horizon",
        "discovery",
        "co",
        "proprietary",
        "technology",
        "support",
        "development",
        "manufacture",
        "novel",
        "biomanufacturing",
        "cell",
        "line",
        "commercial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}